Arkolith/Insider Trading/KALV/Form 4

Sweeny Nicole

Chief Commercial OfficerKalVista Pharmaceuticals, Inc. (KALV) · full profile →Form 4 · filed Jun 11, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
5
1 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 11, 2026Disposed to issuer(D)59K—$00

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 11, 2026Disposed to issuer(D)100K——0
Jun 11, 2026Disposed to issuer(D)40K——0
Jun 11, 2026Disposed to issuer(D)69K——0
Jun 11, 2026Disposed to issuer(D)94K——0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001827505-26-000007) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML